MAP2K7 and hepatocellular carcinoma: MEK inhibitors have also been examined for treating HCC in mouse models [8,9] but they do not appear to be as effective as Sorafenib, most likely due to the broad specificity of Sorafenib, which inhibits other targets besides Raf.